Teclistamab/Talquetamab Combo Shows Early Safety, Efficacy i

Teclistamab-cqyv in combination with talquetamab showcased early signs of activity with acceptable safety in patients with relapsed/refractory multiple myeloma, according to final results from the phase 1b RedirecTT-1 study.

Related Keywords

, Tocilizumab Actemra , Yaelc Cohen , Andrzejj Jakubowiak , Aviv Sourasky Ichilov Medical Center , International Stating System , Tel Aviv University , University Of Chicago , Department Of Hematology , Sackler School Of Medicine , Tel Aviv Sourasky , Medical Center , Sackler School , Tel Aviv , Teclistamab , Talquetamab , Multiple Myeloma , Myeloma , Redirectt 1 Study , Pasco , D ,